We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





AI-Based Drug Discovery Model Hunts for Key Molecule to Block COVID-19

By HospiMedica International staff writers
Posted on 23 May 2020
Print article
AI-based Drug Discovery Model Hunts for Key Molecule to Block COVID-19 (Photo courtesy of Atomwise Inc.)
AI-based Drug Discovery Model Hunts for Key Molecule to Block COVID-19 (Photo courtesy of Atomwise Inc.)
There are presently 15 research collaborations underway to enable academic researchers to discover novel therapies for the COVID-19 pandemic and those in the future using advanced artificial intelligence (AI) technology developed by Atomwise Inc. (San Francisco, CA, USA).

By using predictive models and AI, Atomwise which uses AI for small molecule drug discovery, and its collaborators seek to raise the probability of success for future therapies. Each collaborative project will develop drug candidates with demonstrable broad-spectrum capability, providing potential long-term benefit for future coronavirus outbreaks. Overall, the 15 global research efforts span a wide variety of approaches, including different mechanisms of action, a mixture of viral and human/host target proteins, and targeting conserved regions of proteins that may be recognized even in mutated strains. In addition, many proteins targeted by the academic collaborators have previously been deemed “undruggable” due to their unknown structure or involvement in complex protein-protein interactions. Taken together, the combination of novel approaches could expand the repertoire of therapeutic approaches available for a future outbreak.

Several projects are part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) program, which enables researchers to accelerate the translation of their research into treatments. In support of each collaboration, scientists at Atomwise will use AtomNet, the company’s patented AI screening technology, to predict the binding of millions or billions of small molecules to a protein of interest identified by the academic researcher as a potential target for COVID-19, narrowing down to a few hundred predicted hit molecules. Atomwise then sources and ships a subset of these predicted compounds to partnering laboratories for testing biochemical potency and selectivity, advancing the most promising compounds for further development as drug candidates.

“Atomwise’s AI screening technology is used to predict the binding of more than 10 million small molecules to a protein of interest, and far exceeds what could be accomplished through traditional laboratory screening methods,” said Dr. Stacie Calad-Thomson, vice president and head of Artificial Intelligence Molecular Screen (AIMS) Partnerships at Atomwise. “With Atomwise’s AIMS Awards program, our hope is to democratize access to AI during the early stages of preclinical drug development and enable academics to contribute to the pandemic response who might not have the opportunity otherwise.”

Related Links:
Atomwise Inc.

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Single Cavity Combination Warmer
EC550BL

Print article

Channels

Critical Care

view channel
Image: Researchers have developed an advanced shear-thinning hydrogel for aneurysm repair (Photo courtesy of TIBI)

New Hydrogel Features Enhanced Capabilities for Treating Aneurysms and Halting Progression

Aneurysms can develop in blood vessels in different body areas, often as a result of atherosclerosis, infections, inflammatory diseases, and other risk factors. These conditions lead to chronic inflammation,... Read more

Surgical Techniques

view channel
Image: The living replacement knee will be tested in clinical trials within five years (Photo courtesy of ARPA-H)

Living Knee Replacement to Revolutionize Osteoarthritis Treatment

Osteoarthritis is the most prevalent type of arthritis, characterized by the progressive deterioration of cartilage, or the protective tissue covering the bone ends, resulting in pain, stiffness, and impaired... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.